Ritonavir

CAS No. 155213-67-5

Ritonavir( A-84538 | ABT-538 )

Catalog No. M12207 CAS No. 155213-67-5

A potent HIV protease inhibitor for treatment of HIV-1 infection.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 43 In Stock
5MG 29 In Stock
10MG 43 In Stock
25MG 68 In Stock
50MG 96 In Stock
100MG 138 In Stock
200MG 198 In Stock
500MG 332 In Stock
1G 491 In Stock

Biological Information

  • Product Name
    Ritonavir
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent HIV protease inhibitor for treatment of HIV-1 infection.
  • Description
    A potent HIV protease inhibitor for treatment of HIV-1 infection; also inhibits cytochrome P450-3A4 (CYP3A4).HIV Infection Approved(In Vitro):Ritonavir (ABT 538) is an inhibitor of CYP3A4 mediated testosterone 6β-hydroxylation with mean Ki of 19 nM and also inhibits tolbutamide hydroxylation with IC50 of 4.2 μM. Ritonavir (ABT 538) is found to be a potent inhibitor of CYP3A-mediated biotransformations (nifedipine oxidation with IC50 of 0.07 mM, 17alpha-ethynylestradiol 2-hydroxylation with IC50 of 2 mM; terfenadine hydroxylation with IC50 of 0.14 mM). Ritonavir is also an inhibitor of the reactions mediated by CYP2D6 (IC50=2.5 mM) and CYP2C9/10 (IC50=8.0 mM). Ritonavir results in an increase in cell viability in uninfected human PBMC cultures. Ritonavir markedly decreases the susceptibility of PBMCs to apoptosis correlated with lower levels of caspase-1 expression, decreases in annexin V staining, and reduces caspase-3 activity in uninfected human PBMC cultures. Ritonavir inhibits induction of tumor necrosis factor (TNF) production by PBMCs and monocytes in a time- and dose-dependent manner at nontoxic concentrations. Ritonavir inhibits p-glycoprotein-mediated extrusion of saquinavir with an IC50 of 0.2 μM, indicating a high affinity of ritonavir for p-glycoprotein. Ritonavir inhibits human liver microsomal metabolism of ABT-378 potently with Ki of 13 nM. Ritonavir combined with ABT-378 (at 3:1 and 29:1 ratios) inhibits CYP3A (IC50=1.1 and 4.6 μM), albeit less potently than Ritonavir (IC50=0.14 μM).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    A-84538 | ABT-538
  • Pathway
    Microbiology/Virology
  • Target
    HIV
  • Recptor
    HIVProtease
  • Research Area
    Infection
  • Indication
    HIV Infection

Chemical Information

  • CAS Number
    155213-67-5
  • Formula Weight
    720.9442
  • Molecular Formula
    C37H48N6O5S2
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in DMSO; H2O:< 0.1 mg/mL
  • SMILES
    CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O
  • Chemical Name
    2,7,10,12-Tetraazatridecanoic acid, 4-hydroxy-12-methyl-9-(1-methylethyl)-13-[2-(1-methylethyl)-4-thiazolyl]-8,11-dioxo-3,6-bis(phenylmethyl)-, 5-thiazolylmethyl ester, (3S,4S,6S,9S)-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Eagling VA, et al. Br J Clin Pharmacol, 1997, 44(2), 190-194. 2. Zeldin RK, et al. J Antimicrob Chemother. 2004 Jan;53(1):4-9.
molnova catalog
related products
  • PDDC inhibitor

    PDDC inhibitor (Phenyl (R)-(1-(3-(3,4-dimethoxyphenyl)-2,6-dimethylimidazo[1,2-b]pyridazin-8-yl)pyrrolidin-3-yl)carbamate) is a selective and highly potent nSMase2 inhibitor.

  • Nef-IN-B9

    Nef-IN-B9 (Nef inhibitor B9) is a small molecule that blocks Nef-dependent Hck activity with IC50 of 2.8 uM.

  • D77

    A potent inhibitor of HIV-1 integrase-LEDGF/p75 interaction; binds to IN and IN(T125A) with Kd of 5.81 and 15.2 uM.